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ABSTRACT OF THE THESIS 
 
Effects of Prenatal Fluoxetine Use on Maternal Microbiome  
and Fetal Dorsal Raphe Nucleus Development 
 
by 
 
Maria Kazantsev 
Master of Science in Physiological Science 
University of California, Los Angeles 2019 
Professor Elaine Y. Hsiao, Chair 
 
 
Selective serotonin reuptake inhibitors (SSRIs) are used as first-line treatments by up to 10% of 
pregnant women suffering from major depression. However, the effects of prenatal SSRI use on 
fetal development are still largely unknown. Serotonin plays crucial roles in the early development 
of the fetal brain, and the fetus depends on a maternal source of serotonin. In humans, 90% of 
serotonin synthesis occurs in the gut, promoted by specific microbiota. In the present study, we 
used a pregnant mouse model to assess for changes in the maternal microbiome, after early prenatal 
fluoxetine gavage. We examined the fetal brain for changes in the development of the dorsal raphe 
nucleus, as well as its axonal projections to the prefrontal cortex. Our results suggest that prenatal 
SSRI use does not result in a significant shift in maternal microbiome, and has no direct effect on 
the development of the endogenous fetal serotonergic system. 
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Introduction 
Major depression is one of the most prevalent health issues affecting the global human 
population today. It is the leading cause of disability worldwide, with the World Health 
Organization (WHO) reporting over 322 million people affected (World Health Organization, 
2017). In the United States alone, approximately 16.2 million adults are affected by major 
depression (Substance Abuse and Mental Health Services Administration, 2017), and this rate 
has continued to rise significantly since 2005 (Weinberger et al., 2018). The consequences of this 
illness are pervasive, impairing a person’s ability to perform at school or work, putting strain on 
relationships with friends and family, and in many cases, resulting in suicide (World Health 
Organization, 2017).  
 
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed as first-line treatments 
for depression. However, while they generally have milder side effects compared to other classes 
of antidepressants such as monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants 
(TCAs) (Ferguson, 2001), SSRIs are still far from an ideal solution. Several side effects are 
associated with SSRI use, including nausea and gastrointestinal issues, drowsiness, disturbed 
sleep rhythms, and sexual dysfunction (Ferguson, 2001; Kostev et al., 2014). Furthermore, the 
mechanism of action for SSRIs is not fully understood. Although SSRIs are known to inhibit the 
serotonin transporter (SERT), the direct impact of increased extracellular serotonin on areas 
implicated in depression is still unclear. As a result, there is currently no defined protocol for 
treatment of depression. The efficacies of different drugs vary from person to person, and a 
number of large-scale meta-analyses have been unable to adequately assess which products work 
best, or run the smallest risk of side effects (Jia et al., 2016; Magni et al., 2013; Cipriani et al., 
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2016). Thus, although the use of SSRIs is extremely common (Pratt et al., 2017), there are still 
many gaps in our understanding about the biological effects of these drugs.  
 
SSRIs in Pregnancy and Fetal Brain Development  
This gap in knowledge for how SSRIs work mechanistically is a particular concern for pregnant 
women, 10-20% of whom suffer from major depression at some point throughout their 
pregnancy (Dubovicky et al., 2017; O’Keane & Marsh, 2007). Of these women, approximately 
10% take antidepressants during pregnancy (Furu et al., 2015). Unfortunately, while the 
treatment of perinatal depression eliminates certain risk factors associated with mental illness, 
studies show that SSRIs also reach the fetus in pregnant mothers (Hendrick et al., 2003), with 
both the drug and its catabolic derivatives diffusing passively across the placenta, and making 
their way into the fetal bloodstream (Heikkinen et al., 2002). These molecules also reach the 
developing fetal brain, at first due to the absence of a fully developed blood-brain barrier, and 
later crossing it with the help of transport proteins (Zhao et al., 2015; Rochat et al., 1999). 
During embryogenesis, well before the birth of serotonergic neurons in the dorsal raphe nucleus 
(Bonnin et al., 2011; Daubert & Condron, 2010), serotonin from the mother plays crucial roles in 
early development of the offspring, impacting stages for cleavage, gastrulation and neurulation 
(Moiseiwitsch, 2000). 5-HT receptors, transporters, and degrading enzymes appear throughout 
the fetal brain early during gestation, implicating a role for serotonin in early neurodevelopment 
(Bonnin et al., 2011). However, studies that specifically test this hypothesis are lacking. We 
therefore examine as Aim 2 of my thesis project whether maternal SSRI treatment during 
pregnancy alters fetal neurodevelopment of the offspring.  
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SSRIs and the Microbiome 
Despite the importance of the serotonergic system during fetal development, and findings that 
SSRIs taken by pregnant mothers can cross transplacentally into the fetus, the risks of maternal 
SSRI use on fetal development in humans are still unclear. While some studies report birth 
defects such as spontaneous abortions, preterm births, decreased intrauterine growth rates, and 
decreased birth weights as a result of maternal SSRI use, others find no statistically significant 
effects (Dubovicky et al., 2017; Zwink & Jenetzky, 2018). Furthermore, several meta-analyses of 
the literature have concluded that the data is too limited, the methods are problematic, and there 
is a strong need for more precise examination of the relationship between maternal SSRI use and 
fetal development (Furu et al., 2015; Zwink & Jenetzky, 2018; Gentile, 2011). This variability 
parallels the finding that non-pregnant patients with major depression vary in their 
responsiveness to SSRIs. As such, many studies are examining physiological factors that 
contribute to differences in the efficacy and effects of SSRIs across individuals. The gut 
microbiota is increasingly implicated as an important factor that modulates human responses to 
various xenobiotics, including SSRIs (Spanogiannopoulos et al., 2016). The microbiome 
interacts with drugs that pass through the GI tract, often transforming molecules from active to 
inactive states, or vice versa, before they even reach their target tissues. The microbiome also 
modulates host metabolism and transport, and may therefore have an indirect impact on the 
efficacy of drugs (Spanogiannopoulos et al., 2016). Moreover, 90% of the body’s serotonin 
production occurs in enterochromaffin cells, which line the intestinal tract. Within these cells, 
serotonin synthesis is stimulated by metabolites from the gut microbiome (Yano et al., 2015). 
Therefore, the profile of gut bacteria may also be impacted by SSRIs in turn. In fact, a recent 
study tested over 1000 drugs against 40 representative strains from the microbiome, concluding 
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that 24% of these drugs, including the common SSRI fluoxetine, inhibited the growth of at least 
one bacterial strain (Maier et al., 2018). Other studies have also found that SSRI use is associated 
with alterations in the gut microbiome (Jackson et al., 2018), raising the question of whether 
microbial interactions with SSRIs may modify their effects on host physiology. Therefore, we 
examine as Aims 1 and 3 of my thesis project the question of whether the maternal gut 
microbiome is altered in response to maternal SSRI treatment, and whether the gut microbiome 
is necessary for the effects of maternal SSRI use on fetal neurodevelopment.  
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Experimental Aims  
My thesis project aims to uncover answers to these fundamental questions regarding maternal 
SSRI use, interactions between the microbiome and SSRIs, and effects of maternal SSRI use on 
fetal neurodevelopment:  
 
1. Does SSRI use during pregnancy change the maternal microbiome? 
2. Does perinatal SSRI use influence developmental outcomes in the fetus?  
3. Are developmental changes in fluoxetine-exposed embryos mediated by the maternal 
microbiome? 
 
To tackle these questions, we used a pregnant mouse model (Figure 1). Mice were randomly 
divided into three groups: a vehicle/control group treated with saline during the second trimester 
of pregnancy (SAL), an experimental group treated with fluoxetine (FLX) during pregnancy, and 
a third group in which the microbiome was first depleted with antibiotics, then treated with 
fluoxetine during pregnancy (AF). The latter is a control for the FLX group, to discern whether 
developmental consequences are due to changes in microbiome, or other effects of SSRI 
treatment. We chose to work with fluoxetine because it is among the most commonly prescribed 
SSRIs on the market, as the active ingredient in brand-name drugs such as Prozac (Cipriani et al, 
2016).  
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Materials and Methods 
Mice and antibiotic treatment  
Specific pathogen free (SPF) C57BL/6J mice from the Jackson laboratory were group housed in 
ventilated cages, with free access to standard rodent chow and water ad libitum. The holding 
room maintains a controlled temperature (22-25°C) and humidity, as well as a 12-hour light/dark 
cycle. Prior to breeding, bedding from all cages was mixed every 3 days to ensure similar 
exposure to bacteria, and thus homogenize the gut microbiota across all mice. At approximately 
four weeks of age, all male and female mice in the antibiotic-fluoxetine (AF) group began an 
oral gavage with an antibiotic cocktail of vancomycin (50 mg/kg), neomycin (100 mg/kg), and 
metronidazole (100 mg/kg). 200 µl of the cocktail was administered twice daily by oral gavage, 
at 8:00 and 17:00, for 7 days. Throughout the gavage and thereafter, the antibiotic group was 
maintained by adding 600 µl each of ampicillin (1g/3mL), neomycin (1mg/mL) and vancomycin 
(1g/6mL) to 200 mL of sterile drinking water. During this period the saline and fluoxetine groups 
were also gavaged twice daily with 200 µl of saline solution, for 7 days. 
 
Timed mating and fluoxetine treatment 
All mice were then paired for breeding, and females were checked daily for vaginal plugs. The 
day of post-coital vaginal plug formation was considered embryonic day 0.5 (E0.5), after which 
dams were separated and monitored for weight gain over 7 days. On day E7.5 (approximately the 
end of the first trimester), dams that gained at least 1.5 grams began an 8-day gavage with either 
a saline or fluoxetine hydrochloride solution (4 mg/ml, Santa Cruz). A dosage of 10 mg/kg was 
administered daily at 8:00, as used in previous studies (Rodríguez-Gaztelumendi et al., 2009; 
Machado et al., 2012). At E14.5 mouse dams were sacrificed by cervical dislocation.  
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The E14.5 time point was chosen to align with a few key developmental events. Serotonergic 
neurons appear in the dorsal raphe nucleus (DRN) around E10.5, at which time the embryo also 
begins to generate its own tryptophan hydroxylase (TPH2), an enzyme essential for serotonin 
synthesis in the brain (Daubert et al., 2011; Côté et al., 2006). By E12.5 the axons of 
serotonergic neurons begin projecting from the DRN towards targets such as the hypothalamus, 
amygdala, ventral tegmental area (VTA), hippocampus, and prefrontal cortex (Michelsen et al., 
2007). At this time the embryo also develops a large portion of its serotonin receptors and 
produces substantially more TPH2. However, it is still dependent on maternal sources of 
serotonin until approximately E16.5 (Bonnin et al., 2006; Côté et al., 2006). Therefore, 
examining fetal development at embryonic day 14.5 ensures that we can visualize dorsal raphe 
neurons as they project towards targets in the brain, but also that the fetus remains vulnerable to 
the effects of fluctuating maternal serotonin levels. 
 
16S rDNA sequencing  
Fecal samples were collected for the saline and fluoxetine groups on gestational days E3, E6, E8, 
E11 and E14.5, and kept frozen at -80°C until DNA extraction. We collected a total sample size 
of N = 7 for each treatment group, and AF samples were not sequenced because the microbiome 
is depleted in these animals. To prepare the 16S library for sequencing, bacterial genomic DNA 
was extracted from mouse fecal samples using the MoBio PowerSoil® DNA Isolation Kit, and 
purified using the QIAquick PCR Purification Kit (Qiagen). Next, the sequencing library was 
generated according to methods adapted from Caporaso et al. (2012). The V4 regions of the 16S 
rDNA gene were PCR amplified using universal primers barcoded with unique oligonucleotides, 
Illumina adaptors, and 30 ng of the extracted genomic DNA. The PCR reaction was set up in 
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triplicate, and the product was then purified again using the Qiaquick PCR purification kit 
(Qiagen). DNA concentration was quantified using a BioTek Synergy H1 Multi-Mode 
Microplate Reader, and approximately 250 ng of purified PCR product from each sample was 
pooled and sequenced by Laragen, Inc. Sequencing was performed using the Illumina MiSeq 
platform and 2 x 250bp reagent kit for paired-end sequencing. Operational taxonomic units 
(OTUs) were chosen by open reference OTU picking based on 99% sequence similarity to the 
most recent Greengenes 13_8 database. Taxonomy assignment and rarefaction were performed 
using QIIME2-2019.1 (Caporaso et al., 2018).  
 
Immunohistochemistry 
To analyze axon development in the fetus, we used embryos collected from pregnant dams at 
embryonic day 14.5 (see Materials and Methods). Embryos were quickly collected and fixed in a 
4% paraformaldehyde solution for 1 day, after which they are transferred to a 30% sucrose 
solution for cryoprotection. After a week in sucrose, embryos are frozen in OCT (Tissue-Tek, 
VWR) and preserved at -80°C. Using a cryo-microtome, embryos were cut sagittally at 10 µm 
and mounted on glass slides (Superfrost Ultra Plus, ThermoFisher Scientific), with 10 serial 
sections per embryo. These were stored at -20°C. In preparation for immunohistochemistry, 
slides were incubated in DAKO antigen retrieval solution (Agilent) at 90°C for two minutes, 
washed, and then incubated for 1 hour at room temperature with a 10% natural donkey serum 
solution. After another wash cycle, slides were incubated with primary antibodies for 30 hours at 
4°C. The following antisera were used: anti-5-HT (rat monoclonal, Abcam, ab6336, 1:100), anti-
SERT (rabbit polyclonal, Abcam, ab9726, 1:500), and anti-TPH2 (goat polyclonal, US 
Biological 208476, 1:500). Slides were incubated with secondary antibodies for 1 hour at room 
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temperature, using antisera from ThermoFisher Scientific (donkey anti-rat, Alexa Fluor 488, 
1:1000; donkey anti-goat, Alexa Fluor 568, 1:1000; donkey anti-rabbit, Alexa Fluor 647, 
1:1000). Sections were covered with glass cover slips (@@) and Prolong Gold antifade reagent 
with DAPI (ThermoFisher Scientific), air-dried for one hour, and maintained at 4°C. The final 
sample size for each group was N = 8 embryos for the saline (SAL) group, N = 6 embryos for the 
fluoxetine (FLX) group, and N = 5 embryos for the antibiotic-fluoxetine (AF) group.  
 
Image Acquisition  
Slides were imaged using a 20X objective on a Zeiss LSM780 confocal microscope, equipped 
with an Argon laser (488 nm), a Diode 561 nm and HeNe 633 nm. Images were acquired across 
eight Z-sections, scanning a total of 5.31 µm at a 1024 x 1024 pixel resolution. Scans were tiled 
in the Zen Black Edition software and stitched using the Zen 2.1 (Blue Edition) software.  
 
Quantification for IHC Staining 
To compare 5HT, SERT and TPH2 levels in each group, sagittal E13.5 and E15.5 brain sections 
from the Allen Developing Mouse Brain Atlas were used as a reference to locate the midpoint of 
each embryo brain (2008). Beginning at the midpoint, five consecutive brain sections were 
analyzed for each embryo, as a means of consistently quantifying both DRN neurons and axon 
projections in a medial-to-lateral progression, spaced 100 µm apart (Figure 2). DRN neurons 
were counted using the ImageJ Puncta Analyzer plugin developed by the Eroglu Lab at Duke 
University, using methods adapted from Ippolito & Eroglu, 2010. A single region of interest 
(ROI) was generated to designate the DRN region and used for all sections, recording 
colocalized puncta for 5HT and SERT, as well as 5HT and TPH2 (Figure 3A). Axon projections 
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were quantified in ImageJ using three separate, but consistent, ROIs for all sections (Figure 3B). 
Integrated Density readings for these ROIs were used to assess signal intensity, with additional 
readings recorded in non-staining regions, normalized to the same area and subtracted from the 
original measures to account for background noise. Axon projections were also quantified after 
setting an intensity threshold for each channel, thus providing a count of individual puncta in 
addition to staining intensity. 
 
Statistical Analysis 
Imaging data was summed for all five sections in each embryo. All imaging data was analyzed 
using Prism 8 software. Comparisons between SAL and FLX groups were then performed using 
a two-tailed unpaired t-test, whereas comparisons between SAL, FLX and AF groups were 
analyzed using a one-way ANOVA. Post-hoc analysis for differences between individual 
gestational time points was performed using Tukey’s Multiple Comparisons Test. 
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Results 
Aim 1: Determine the effects of maternal fluoxetine treatment on the maternal gut 
microbiome 
To determine whether maternal microbiome is altered in response to maternal treatment with the 
SSRI fluoxetine, we sequenced 16S ribosomal DNA of fecal microbiota samples collected from 
pregnant mouse dams. First, we evaluated the alpha diversity of the microbiota, or the number of 
unique bacterial species within each sample. To do this we used the Faith Phylogenetic Diversity 
(PD) metric, calculated for each of the five gestational time points within each treatment group 
(Figure 4). The Faith PD metric is the sum of phylogenetic branches that span a given set of taxa 
on a phylogenetic tree, thereby describing the quantity of phylogenetic differences in a sample, 
or species richness (Faith, 1992; Faith & Baker, 2007). Our results showed no significant 
difference between the saline and fluoxetine groups, when analyzed both as a Kruskal-Wallis 
one-way ANOVA, as well as Kruskal-Wallis pairwise comparisons between each group (Figure 
5A). This indicates no difference in alpha diversity of the microbiota between pregnant dams in 
the saline and fluoxetine groups, regardless of gestational day.  
 
Next, we analyzed beta diversity, or the relative distribution of different types of bacteria 
between groups. We first used principal coordinates analysis (PCoA) to assess similarities and 
dissimilarities between the two groups, plotting each data point at a distance that is relative to its 
dissimilarity from others, and basing the axes on the 2 most significant dimensions of analysis. 
The UniFrac distance used for assembling the PCoA plots can be either unweighted or weighted 
with regards to species abundance. The unweighted calculation is a metric describing 
quantitative differences between groups, as it only takes into account the presence or absence of 
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species within each sample. The weighted calculation, on the other hand, describes qualitative 
differences as well. This is because it takes into account the abundance of each unique species 
and compares it between samples, in addition to the number of species present. Our analysis of 
unweighted results revealed no differences in beta diversity across different timepoints for either 
saline or fluoxetine groups (Figure 6A). Neither group showed clear shifts in clustering as 
gestation progressed, which suggests that there is no change in maternal microbiome 
composition as the fetus develops. Furthermore, there is no separation between saline and 
fluoxetine clusters for any of the gestational timepoints, indicating no significant difference in 
microbiome composition in response to prenatal fluoxetine treatment. Thus, our next step was to 
generate weighted PCoA plots, to assess whether fluoxetine had any effect on species abundance 
(Figure 6B). For the qualitative analysis we again saw a lack of initial clustering for either 
treatment group. Similarly, the saline group shows no clear shift over time. Some samples in the 
fluoxetine group do seem to shift slightly in gestational days E11 and E14, however there is no 
clear clustering for the treatment group as a whole. Additionally, there is still no clear separation 
between saline and fluoxetine groups, suggesting again that prenatal fluoxetine treatment does 
not affect the maternal microbiome. Analyses including the third PCoA axis yielded similarly 
insignificant results. 
 
However, despite seeing no global changes by our PCoA plots, we proceeded to generate a 
microbial taxonomy chart to determine whether select microbial taxa were altered by fluoxetine 
experiment (Figure 7). Using the Qiime 2 software, we were able to assign phylogenetic 
classifications for unique species present in each sample, down to the species level. Results were 
calculated for each treatment group and organized by embryonic day. As seen in Figure 7, the 
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saline group exhibits a relatively constant distribution of the microbiota throughout the 
pregnancy, without any significant changes following the beginning of saline gavage on E7. The 
fluoxetine group, while relatively consistent as well, does suggest some decrease in abundance of 
the Bacteroidia class, while seeing a simultaneous enrichment of the Clostridia class, moving 
from the E3 to E14 time points. However, further statistical analysis showed that these shifts 
were not significant. A test for changes in microbial abundance, using a permutational 
multivariate analysis of variance, or PERMANOVA, revealed no significant difference between 
treatments, across all five days of gestation, for any of the bacterial species identified in the 
original phylogenetic classification.  
 
Taken together, these results indicate that prenatal fluoxetine exposures during the second 
trimester of pregnancy do not have an effect on the bacterial composition of the maternal gut 
microbiome in mice. 
 
Aim 2: Examine effects of maternal fluoxetine treatment fetal neurodevelopment  
Having assessed for changes in microbiome of fluoxetine-treated dams, we continued to 
investigate our second aim: determining whether maternal fluoxetine exposure alters 
neurodevelopment in the fetus itself. Although these effects may not be mediated by changes in 
the maternal microbiome, our experiment may still provide valuable information about SSRI use 
during pregnancy. Therefore, we addressed this question by investigating the developing 
serotonergic system in the fetal brain.  
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The DRN is a bilateral and heterogeneous brainstem nucleus located in the periaqueductal gray 
region between the midbrain and hindbrain (Michelsen et al., 2007; Alonso et al., 2013). 
Although the nucleus contains neurons that utilize a variety of neurotransmitters, including 
dopamine, GABA, and glutamate, serotonin is the primary neurotransmitter in about 70% of 
these neurons (Michelsen et al., 2007). Thus, the DRN is well known as the origin of extensive 
serotonergic connections in the brain, projecting axons to targets including the substantia nigra, 
caudate putamen, hippocampus and entorhinal cortex, PVN of the thalamus, central amygdala, 
lateral hypothalamus, and importantly, the prefrontal cortex (Michelsen et al., 2007). Because of 
its extensive participation in serotonergic signaling, the DRN is a potential target for 
developmental changes as a result of maternal SSRI use, and could have downstream effects in a 
variety of brain regions. For example, a recent study investigated the effects of early postnatal 
SERT manipulation (P2-P10) on the development of axons that originate in the prefrontal cortex 
and innervate the DRN (Soiza-Reilly et al., 2018). Both ablation of SERT and postnatal 
fluoxetine treatment resulted in significant changes in axon development, including 
hyperinnervation of the DRN by axons from the prefrontal cortex. Therefore, we hypothesized 
that maternal SSRI exposure may alter the reciprocal innervation from DRN to prefrontal cortex. 
The outgrowth of these projections, of which more than 80% are serotonergic, begins during 
prenatal brain development - around E12.5 in mice (Michelsen et al., 2007). Here we examined 
the effects of oral maternal fluoxetine administration on fetal DRN neurons and their axons at the 
E14.5 time point, because it is ideal for visualizing the early development of axonal projections 
to the prefrontal cortex. 
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Serotonergic Markers 
To assess for the presence and outgrowth of axons originating in the DRN, we used three 
different markers that are essential to the serotonergic system: 5-HT itself, the serotonin 
transporter SERT, and the enzyme tryptophan hydroxylase 2 (TPH2), which is crucial for 
serotonin synthesis in the brain. Because serotonin is produced by serotonergic neurons, it is the 
most direct way to label and track them as they extend to various areas in the brain. However, we 
decided to use additional markers for several reasons. First, maternal serotonin is present 
throughout the fetal brain in addition to serotonergic cells and may therefore lead to nonspecific 
labeling in areas where it acts as a developmental guidance cue (Daubert et al., 2010). 
Additionally, while the serotonin antibody can reliably mark cells in the DRN itself, the axons 
that project specifically from the DRN to the prefrontal cortex appear as very fine varicosities in 
the sagittal plane (Michelsen et al., 2007). These projections can sometimes be difficult to 
distinguish from some levels of background staining, so the use of additional markers allows us 
to locate and quantify these axons with greater certainty. 
 
We decided to use SERT as a second marker. Much like serotonin itself, SERT occurs in all 
serotonergic neurons (Daws & Gould, 2011), and has been used to label serotonergic axons 
reliably in previous work (Bonnin et al., 2011). Furthermore, it is a crucial regulator of 
extracellular serotonin levels and the functional target of SSRIs. However, in the brain, SERT is 
transiently expressed in a non-monoaminergic population of neurons in the internal capsule 
(Verney et al., 2002). Therefore, it is also best paired with another stain, such as 5-HT.  
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Finally, the enzyme TPH2 was used as a third marker, because it is essential to 5-HT production 
in the brain. TPH2 is present in all raphe neurons and begins to appear as early as E10.5, 
ensuring that it will be present, at least to some extent, in our brain sections at E14.5. As it is not 
present elsewhere in the brain, otherwise occurring only in the myenteric plexus of the 
gastrointestinal tract (Côté et al., 2006), TPH2 is a highly specific marker for serotonergic 
neurons. 
 
Prenatal fluoxetine does not affect DRN neuron development or navigation of serotonergic axons 
to the prefrontal cortex 
Quantification of neurons in the DRN was performed by assessing colocalization of puncta 
between the 5-HT and SERT channels, and also between the 5-HT and TPH2 channels (Figure 
8). The use of colocalization for quantifying staining ensured that the analyzed cells were truly 
part of the serotonergic population within the DRN. However, there was no visible difference in 
DRN staining between SAL and FLX embryos (Figure 8A-D), and indeed, our results did not 
differ between treatment groups (Figure 8E, 8F). One thing we noticed, however, was that there 
was a significant disparity in the number of SERT+ and TPH2+ puncta labeled in the DRN. This 
is not entirely unexpected because endogenous production of serotonin, in which the TPH2 
enzyme plays a crucial role, is not fully developed until approximately E16.5 in fetal mouse 
brain. In addition, unlike 5-HT and SERT, TPH2 has not been implicated as a guidance cue in 
early brain development and is therefore not expected to appear as robustly as other markers at 
the E14.5 time point. However, to rule out the possibility that prenatal fluoxetine exposure has an 
impact on the production of TPH2 in serotonergic neurons, we assessed the ratio of TPH2+ to 
SERT+ puncta for each treatment group (Figure 8G). A two-tailed test showed no significant 
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difference in TPH2/SERT puncta ratio between SAL and FLX embryos, suggesting that TPH2 
development in the DRN is not adversely affected by prenatal fluoxetine exposure (p = 0.6382). 
 
Next, we looked at serotonergic axon projecting from the DRN to the prefrontal cortex (Figure 
9). Two-tailed t-test analysis with Welch’s correction showed no statistically significant 
differences in integrated density readings for 5-HT, SERT, or TPH2 channels (p = 0.3755, 
0.6101, and 0.5375, respectively), between SAL and FLX embryos (Figure 9B, 9E, 9H). 
Similarly, no significant differences were found for quantitative analysis of puncta analyzed 
using a visual threshold, between SAL and FLX embryos in the 5-HT, SERT, and TPH2 
channels (p = 0.1813, 0.7875, and 0.8854, respectively, Figure 9C, 9F, 9I). We also assessed 
staining differences independently for each of the three axon regions, across all three channels. 
Two-way ANOVA analyses and pairwise comparisons for both integrated density readings and 
puncta counts showed no significant difference between saline and fluoxetine groups in all three 
channels (Figure 10). 
 
Taken together, these results suggest that the development of serotonergic neurons in the DRN, 
as well as the navigation of serotonergic axon projections to the forebrain, are unaffected by 
prenatal fluoxetine use during the second trimester of gestation in mice.  
 
Aim 3: Assessing the role of the maternal microbiome in mediating effects of fluoxetine 
treatment on fetal brain development 
In addition to looking at the development of DRN neurons and axon projections in saline- and 
fluoxetine-treated dams, we also assessed whether these structures may be mediated by the 
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maternal microbiome. For this purpose, we introduced the antibiotic-fluoxetine (AF) group, 
where mothers are depleted of their microbiome by antibiotic treatment, and subsequently treated 
with fluoxetine throughout gestation. By comparing the effects of fluoxetine treatment between 
pregnant mice with full microbiomes and those with virtually absent microbiomes, we initially 
aimed to assess whether changes in fetal brain development are due to interactions with the 
microbiome (if changes observed in the fluoxetine group are no longer seen in the antibiotic-
fluoxetine group), or due to some other mechanism, elsewhere in the system (if the fluoxetine 
and antibiotic-fluoxetine groups were to exhibit the same phenotype). Although we did not see 
significant differences in maternal microbiome composition between saline and fluoxetine 
groups, nor in the development of DRN neurons and axon projections to the cortex, this third 
comparison was still useful to assess whether fluoxetine can be harmful to the fetus after 
maternal microbiome depletion. To quantify serotonergic cells in the DRN and axon projections 
to the PFC, we used the same staining and imaging techniques as those outlined in Aim 2.  
 
Depleted maternal microbiome does not affect the impact of prenatal fluoxetine use on DRN 
neuron development or navigation of serotonergic axons to the prefrontal cortex 
As in Aim 2, quantification of neurons in the DRN was performed by assessing colocalization of 
puncta between 5-HT and SERT channels, as well as 5-HT and TPH2 channels (Figure 11). 
Similarly, our results showed no statistically significant differences between SAL, FLX and AF 
groups (Figure 11E, 11F). In addition, calculation of TPH2+ to SERT+ puncta ratio showed no 
significant difference between SAL, FLX and AF embryos, confirming once more that TPH2 
development in the DRN is not adversely affected by prenatal fluoxetine exposure (Figure 11G). 
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Next, we looked again at serotonergic axon projections from the DRN to the prefrontal cortex 
(Figure 12). Analysis by one-way ANOVA showed no statistically significant differences in 
integrated density readings for 5-HT, SERT, or TPH2 channels (p = 0.8058, 0.9135, and 0.8642, 
respectively), between SAL, FLX and AF embryos (Figure 12B, 12E, 12H). Similarly, no 
significant differences were found for quantitative analysis of puncta reaching threshold levels 
between SAL, FLX and AF embryos in 5-HT, SERT, and TPH2 channels (p = 0.3745, 0.7263, 
and 0.2753, respectively, Figure 12C, 12F, 12I). Once again, we assessed staining differences 
independently for each of the three axon regions as well, across all three channels. Two-way 
ANOVA analyses and pairwise comparisons, for both integrated density readings and puncta 
counts, showed no significant difference between SAL, FLX and AF groups in all three channels 
(Figure 13). 
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Discussion 
In summary, we have found no evidence to suggest differences in maternal microbiomes 
between pregnant mouse dams treated with fluoxetine during the second week of gestation, and 
those treated with saline. A thorough analysis of 16S rDNA sequences between the two groups 
indicated no differences in alpha diversity (species richness), unweighted beta diversity 
(difference in unique species between groups), or weighted beta diversity (difference in species 
type and abundance between groups). Even pairwise comparisons yielded no significant 
differences between groups for specific gestational time points. This suggests that the maternal 
microbiome, though known to fluctuate throughout gestation for many women (Santacruz et al., 
2010), is not impacted by the SSRI fluoxetine when administered over the course of the second 
trimester in mice. 
 
Furthermore, our results did not show any significant changes in the number of serotonergic cells 
located in the DRN, when examined across saline, fluoxetine, and antibiotic-fluoxetine groups. 
This was confirmed by the use of three different serotonergic markers, assessed for colocalized 
puncta in the DRN region. Likewise, we failed to see changes in the development of axons that 
project from cell bodies in the DRN towards the prefrontal cortex in the forebrain. Quantification 
from three axon regions, for all three experimental groups (SAL, FLX and AF), yielded no 
significant results, whether compared individually for each axon region or as a sum representing 
the entire area stained, for developing mouse brain at gestational day E14.5.  
 
Altogether, these results support the idea that fluoxetine use during pregnancy does not have an 
effect on bacterial composition in the maternal microbiome. Furthermore, prenatal fluoxetine use 
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during the second week of gestation in mice does not appear to affect the development of the 
brain’s main serotonergic system, whether by means of the microbiome (as verified by saline-
fluoxetine comparisons) or possible off-target effects of prenatal fluoxetine exposure (as seen by 
the lack of differences between saline, fluoxetine and antibiotic-fluoxetine groups). In general, 
this finding provides a positive outlook for those who seek to control major depression during 
pregnancy, without causing harm to the developing fetus. 
 
Thus, despite the fact that the DRN and its projections comprise the main serotonergic system in 
the brain, our results suggest that its development is not dependent on feedback from circulating 
5-HT levels in the fetal brain, or elsewhere in the developing embryo. This is supported by recent 
research investigating the development of serotonergic neurons in the brain, where 5-HT was not 
implicated as a key signaling factor (Deneris & Gaspar, 2018). Furthermore, while studies have 
shown that cell cultures of raphe neurons respond to 5-HT and increase axon growth, in vivo 
genetic models fail to show deficits in the development of the central serotonergic system, 
regardless of whether brain 5-HT was depleted or increased (Gaspar et al., 2003). Nevertheless, 
in addition to the general role of serotonin in modulating neuronal proliferation, differentiation, 
and apoptosis, several neuronal circuits in the brain are specifically influenced by serotonergic 
signaling in early development. This is evidenced by early transient expression of the serotonin 
transporter, SERT, and accumulation of 5-HT in neuronal populations that do not synthesize it 
themselves, including the thalamus, hypothalamus, and limbic system (Gaspar et al., 2003). 
However, while the specific function of 5-HT has been studied extensively as a guidance cue for 
thalamocortical axons projecting to the somatosensory cortex (van Kleef et al., 2012), a process 
in which the hypothalamus also plays a role, its participation in the early development of regions 
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such as the hippocampus and amygdala has not yet been determined (Shimogori et al., 2010; 
Bocchio et al., 2016).  
 
Current literature addressing these concerns is largely focused on early postnatal administration 
of fluoxetine or other SSRIs (Ansorge et al., 2004; Gur et al., 2013). But while these studies do 
often show behavioral deficits in rodent offspring, the varied timing between experiments makes 
it difficult to determine with certainty whether SSRI exposure is actually responsible. On the one 
hand, the first 20 days of postnatal brain development in rodents generally coincides with the 
third trimester of human gestation; on the other, this time point is well past the developmental 
timelines for multiple neuronal circuits, including the serotonergic system described here, as well 
as other systems influenced by serotonergic signaling such as the hippocampus (Semple et al., 
2013).  
 
A more clinically applicable perspective has been pursued in countless studies investigating 
behavioral outcomes in children who were exposed to SSRIs prenatally. Many of these studies 
have suggested associations between prenatal fluoxetine exposure and the development of 
psychiatric diseases such as depression, anxiety disorders, drug addiction and autism in children 
(Gur et al., 2013). However, these studies vary greatly in timing of SSRI exposure, the types of 
SSRIs administered, and the way that subjects are assessed for such behaviors in early childhood. 
The ultimate result of such varied conditions is a large number of outcomes that do not seem to 
agree with each other in any reliable fashion. A recent abstract presented by Dr. Sarah 
Hutchinson and senior author, Dr. Tim Oberlander at the 2018 Pediatric Academic Societies 
meeting even suggests that long-term outcomes for children with prenatal SSRI exposure may 
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confer improved executive function skills by 12 years of age (Pediatric Academic Societies, 
2018). 
 
Therefore, the development of a standard model and procedure is key to future studies 
investigating the impact of prenatal SSRI exposure on developmental outcomes, so as to 
elucidate greater clarity on the subject. Even within our own model, subsequent testing of 
behavioral outcomes in the offspring would be beneficial for determining whether prenatal 
fluoxetine exposure truly results in adverse behavioral outcomes. Additional groups of pregnant 
dams could also be assessed under stressed and non-stressed conditions, to simulate the maternal 
stress typically associated with major depression during pregnancy, and which is often thought to 
be a confounding factor with SSRI use that is difficult to distinguish in clinical studies (Gur et 
al., 2013). Once an effective model is developed, with confirmed behavioral outcomes, further 
testing of the neuronal circuits outlined above will be essential.  
 
Despite the growing number of studies investigating prenatal SSRI exposure in rodent and 
human models alike, there is still an overwhelming lack of inquiry regarding the mechanisms 
that are potentially modulating the variety of behavioral outcomes we have seen in the literature. 
Here we have shown significant support against any modifications to maternal microbiome as a 
result of prenatal fluoxetine exposure during the second trimester in mice, as well as lack of 
changes in the developing serotonergic DRN system in fetal mouse brain. Future research in the 
field should investigate the effect of early gestational exposure to fluoxetine on other key 
neuronal circuits, particularly those influenced by 5-HT in early development. 
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Figures 
 
Figure 1: Experimental timeline for pregnant mouse model for control (SAL) and 
treatment (FLX, AF) groups. Mice were randomly divided into one of three groups, after 
which they all underwent one week of either saline (SAL and FLX groups) or antibiotic (AF) 
gavage, administered twice daily. Thereafter the AF group was maintained by adding antibiotics 
to drinking water. After a week of oral gavage mice were paired for breeding and checked for 
pregnancy daily. Vaginal plug dates were noted as embryonic day 0.5 (E0.5). Fecal samples were 
collected and weights measured for all mice on E3 and E6. All dams who gained at least 1.5g in 
the first week began oral gavage with either saline (SAL group) or fluoxetine (FLX and AF 
groups). Pregnant mice were weighed and gavaged daily, with fecal samples collected on E8, 
E11, and E14.5. All mice were sacrificed, and embryos collected, on E14.5. 
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Figure 2: Matched sagittal brain sections moving from lateral to medial brain in E14.5 
mouse embryo. Serial sections were cut on a cryo-microtome in 10-slide sequences, generating 
a distance of 100 µm between each section. Each brain was cut sagittally from the left lateral 
side of the brain, across to the right lateral side, generating 10 total sections for each brain. The 
Allen Developing Mouse Brain Atlas (2008) was used as a reference to locate the midpoint of 
each brain, and five sections projecting laterally from this midpoint were selected for quantifying 
changes in DRN and axon development. Matched representative sections for saline- (SAL), 
fluoxetine- (FLX) and antibiotic/fluoxetine-treated (AF) embryos are presented here. It should be 
noted that the AF group has slightly smaller sections and a faster progression, due to the nature 
of AF mouse embryos, which are typically smaller than wild-type embryos with non-depleted 
maternal microbiomes. No such deficits are known, nor were identified in this experiment, for 
fluoxetine-treated embryos, which matched very well to saline-treated fetal brain sections. 
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Figure 3: Regions of interest (ROIs) used for quantification in DRN and axon projection 
regions. (A) Region of interest drawn for DRN quantification. The same ROI was superimposed 
onto all images analyzed for DRN staining and used to designate the region to be quantified by 
the Puncta Analyzer plugin for ImageJ. (B) For axon quantification, three different regions of 
interest were drawn to span the entirety of the axon progression. The same three ROIs were 
superimposed onto all images analyzed for axon projection staining and used to designate the 
region to be quantified by integrated density analysis and particle analysis with thresholds in 
ImageJ. Region 1 designates the area where axons first project from the midbrain into the 
forebrain. Region 2 contains the bulk of axon projections at this stage in development and passes 
by the developing hypothalamus. Region 2 was designated with care to avoid quantifying axon 
projections moving towards the hypothalamus. Finally, Region 3 collected data for axon 
projections that are near the basal forebrain at E14.5. 
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Figure 4: Faith Phylogenetic Diversity (PD) measurements used to assess alpha diversity in 
pregnant mouse microbiota. The Faith PD metric is used to assess species richness within a 
sample, or how many unique types of bacteria are present in a microbiome. This metric was 
calculated for all gestational timepoints in each treatment group. There was no significant 
difference across groups when compared using a Kruskal-Wallis one-way ANOVA (p = 0.7190).   
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Figure 5: P-values from pairwise comparisons across treatment groups and gestational 
days, for alpha and beta diversity analyses. (A) Post-hoc pairwise comparisons were 
performed for SAL and FLX dams across all 5 gestational timepoints, with p-values from each 
two-tailed t-test shown above. These were assessed in addition to a one-way ANOVA that was 
calculated for all groups (Figure 4). None of the comparisons showed statistically significant 
differences. (B) Pairwise comparisons of p-values generated by the Qiime 2 program for post-
hoc analysis of beta diversity, analyzed in addition to an original PERMANOVA test. None of 
these comparisons showed statistically significant differences between groups. 
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Figure 6: Unweighted and weighted PCoA plots comparing beta diversity for saline and 
fluoxetine groups across five gestational timepoints. (A) Unweighted UniFrac measurements 
were calculated for quantitative analysis of beta diversity, between saline- and fluoxetine-treated 
pregnant dam microbiota. The PCoA plots display five different gestational time points, with 
samples plotted against the two principal coordinate axes. Neither the saline nor the fluoxetine 
group showed any clear shifts in clustering across the five time points. (B) Weighted UniFrac 
measurements are shown for qualitative analysis of beta diversity between saline- and fluoxetine- 
treated pregnant dam microbiota. These PCoA plots take into account the abundance of unique 
species in each sample, in addition to their presence or absence. While there were no clear shifts 
in clustering for the saline group, the fluoxetine group seems to have shifted from a general 
cluster on gestational day E3, which spreads out across the plot by gestational day E14.5. 
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Figure 7 
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Figure 7: Taxonomy chart with relative distribution of bacterial taxa in saline and 
fluoxetine groups. Bacterial taxa for each sample were analyzed by treatment and embryonic 
day. The relative frequency for the top 13 species present across all samples are shown. There 
does not seem to be any fluctuation in the top bacterial species for the saline group. The 
fluoxetine group, however, appears slightly less stable over time, with the taxonomy plot 
seeming to show enrichment in the Clostridia class of bacteria as gestational day increases. 
However, our PERMANOVA calculation across all groups did not identify any bacterial species 
that varied significantly between treatments or gestational days. 
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Figure 8 
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Figure 8: Imaging and quantification of cell bodies in the DRN for saline (SAL) and 
fluoxetine (FLX) groups. (A) SAL and FLX sections showing 5-HT staining for cells in the 
DRN. (B) SAL and FLX sections showing SERT staining for cells in the DRN. (C) SAL and 
FLX sections showing TPH2 staining for cells in the DRN. (D) SAL and FLX sections showing 
overlaid DRN staining for all channels (5-HT, SERT and TPH2). (E) Comparison of DRN cell 
counts between SAL and FLX embryos, quantified by measuring colocalized 5-HT+ and SERT+ 
puncta in the DRN region. A two-tailed t-test between groups showed no significant difference 
between saline and fluoxetine groups (p = 0.6546). (F) Comparison of DRN cell counts between 
SAL and FLX embryos, quantified by measuring colocalized 5-HT+ and TPH2+ puncta in the 
DRN region. A two-tailed t-test between groups showed no significant difference between saline 
and fluoxetine groups (p = 0.8483). (G) The ratio of TPH2+ counts to SERT+ counts was 
quantified to assess whether there was any difference in staining for the two markers, between 
saline and fluoxetine groups. A two-tailed t-test showed no significant difference between 
treatments (p = 0.6382).  
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Figure 9 
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Figure 9: Imaging and quantification of axon projections moving from DRN to PFC in 
saline (SAL) and fluoxetine (FLX) groups. (A) SAL and FLX sections showing 5-HT staining 
for serotonergic axon projections in axon region 2, as depicted by the ROI in Figure 3B. (B) 
Integrated density readings were summed across five brain sections for all SAL and FLX 
embryos, to analyze for 5-HT staining intensity. A two-tailed t-test with Welch’s correction 
showed no significant difference between SAL and FLX embryos (p = 0.3755). (C) 5-HT+ 
puncta were quantified across five brain sections for all SAL and FLX embryos to analyze 
number of axons present. A two-tailed t-test with Welch’s correction showed no significant 
difference between SAL and FLX embryos (p = 0.1813). (D) SAL and FLX sections showing 
SERT staining for serotonergic axon projections in axon region 2. (E) Integrated density readings 
for SERT+ axon projections in SAL and FLX embryos. A two-tailed t-test with Welch’s 
correction showed no significant difference between treatment groups (p = 0.6101). (F) SERT+ 
puncta quantified for axon projections in SAL and FLX embryos. A two-tailed t-test with 
Welch’s correction showed no significant difference between treatment groups (p = 0.7875). (G) 
SAL and FLX sections showing TPH2 staining for serotonergic axon projections in axon region 
2. (H) Integrated density readings for TPH2+ axon projections in SAL and FLX embryos. A two-
tailed t-test with Welch’s correction showed no significant difference between treatment groups 
(p = 0.5375). (I) TPH2+ puncta quantified for axon projections in SAL and FLX embryos. A 
two-tailed t-test with Welch’s correction showed no significant difference between treatment 
groups (p = 0.8854). (J)  SAL and FLX sections showing overlaid serotonergic axon staining for 
all channels (5-HT, SERT and TPH2) in axon region 2. 
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Figure 10 
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Figure 10: Region-specific quantification of axon projections moving from DRN to PFC, 
for saline (SAL) and fluoxetine (FLX) groups. Axon projections were compared between 
groups using both integrated density, to assess the intensity of axon labeling, as well as 
thresholded counts for puncta within each channel, to evaluate presence of axons quantitatively. 
No significant difference was found between saline and fluoxetine groups for any of the three 
regions examined: Axon ROIs 1, 2 and 3 as shown in Figure 3. (A) 5-HT integrated density 
comparison between saline and fluoxetine groups for Axon Region 1 (p = 0.6894), Axon Region 
2 (p = 0.4702), and Axon Region 3 (p = 0.9735). (B) 5-HT puncta comparison between saline 
and fluoxetine groups for Axon Region 1 (p = 0.5901), Axon Region 2 (p = 0.2228), and Axon 
Region 3 (p = 0.9918). (C) SERT integrated density comparison between saline and fluoxetine 
groups for Axon Region 1 (p = 0.9203), Axon Region 2 (p = 0.5876), and Axon Region 3 (p = 
0.9403). (D) SERT puncta comparison between saline and fluoxetine groups for Axon Region 1 
(p = 0.8874), Axon Region 2 (p = 0.9975), and Axon Region 3 (p = 0.9032). (E) TPH2 
integrated density comparison between saline and fluoxetine groups for Axon Region 1 (p = 
0.8980), Axon Region 2 (p = 0.6077), and Axon Region 3 (p = 0.9998). (D) TPH2 puncta 
comparison between saline and fluoxetine groups for Axon Region 1 (p = 0.9480), Axon Region 
2 (p = 0.9963), and Axon Region 3 (p = 0.9859). 
 
 
 
 
 
 
 
38 
 
 
Figure 11: Imaging and quantification of cell bodies in the DRN, with AF group added. (A) 
SAL, FLX and AF sections showing 5-HT staining for cells in the DRN. (B) SAL, FLX and AF 
sections showing SERT staining for cells in the DRN. (C)  SAL, FLX and AF sections showing 
TPH2 staining for cells in the DRN. (D) SAL, FLX and AF sections showing overlaid DRN 
staining for all channels (5-HT, SERT and TPH2). (E) Comparison of DRN cell counts between 
SAL, FLX and AF embryos, quantified by measuring colocalized 5-HT+ and SERT+ puncta in the 
DRN region. A one-way ANOVA between groups showed no significant difference between 
treatments (p = 0.6280). (F) Comparison of DRN cell counts between SAL, FLX and AF embryos 
quantified by measuring colocalized 5-HT+ and TPH2+ puncta in the DRN region. A one-way 
ANOVA between groups showed no significant difference between treatments (p = 0.7581). (G) 
Ratio of TPH2+ to SERT+ counts between SAL, FLX and AF groups. A one-way ANOVA showed 
no significant difference between treatments (p = 0.8598). 
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Figure 12: Imaging and quantification of axon projections moving from DRN to PFC, in with 
AF group added. (A) SAL, FLX and AF sections showing 5-HT staining for serotonergic axon 
projections in axon region 2. (B) Integrated density readings for 5-HT+ axon projections in SAL, 
FLX and AF embryos. A one-way ANOVA showed no significant difference between treatment 
groups (p = 0.8058). (C)  5-HT+ puncta quantified for axon projections in SAL, FLX and AF 
embryos. A one-way ANOVA showed no significant difference between treatment groups (p = 
0.3745). (D) SAL, FLX and AF sections showing SERT staining for serotonergic axon projections 
in axon region 2. (E) Integrated density readings for SERT+ axon projections in SAL, FLX and AF 
embryos. A one-way ANOVA showed no significant difference between treatment groups (p = 
0.9135). (F) SERT+ puncta quantified for axon projections in SAL, FLX and AF embryos. A one-
way ANOVA showed no significant difference between treatment groups (p = 0.7263). (G) SAL, 
FLX and AF sections showing TPH2 staining for serotonergic axon projections in axon region 2. 
(H) Integrated density readings for TPH2+ axon projections in SAL, FLX and AF embryos. A one-
way ANOVA showed no significant difference between treatment groups (p = 0.8642). (I) TPH2+ 
puncta quantified for axon projections in SAL, FLX and AF embryos. A one-way ANOVA 
showed no significant difference between treatment groups (p = 0.2753). (J) SAL, FLX and AF 
sections showing overlaid serotonergic axon staining for all channels (5-HT, SERT and TPH2) in 
axon region. 
 
40 
 
 
Figure 13 
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Figure 13: Region-specific quantification of axon projections moving from DRN to PFC, with 
AF group added. Tukey’s multiple comparisons test was used to perform pairwise analyses across 
the three treatment groups. The p-values reported here correspond to SAL vs. AF and FLX vs. AF 
comparisons, respectively. (A) 5-HT integrated density comparison between SAL, FLX, and AF 
groups for Axon Region 1 (p = 0.8656, 0.9652), Axon Region 2 (p = 0.9952, 0.4936), and Axon 
Region 3 (p = 0.8980, 0.8135). (B) 5-HT puncta comparison between SAL, FLX, and AF groups 
for Axon Region 1 (p = 0.2379, 0.7828), Axon Region 2 (p = 0.5185, 0.8887), and Axon Region 3 
(p = 0.7506, 0.8354). (C) SERT integrated density comparison between SAL, FLX, and AF groups 
for Axon Region 1 (p = 0.9614, 0.9950), Axon Region 2 (p = 0.9460, 0.4703), and Axon Region 3 
(p = 0.9546, 0.8357). (D) SERT puncta comparison between SAL, FLX, and AF groups for Axon 
Region 1 (p = 0.7495, 0.9613), Axon Region 2 (p = 0.5917, 0.5903), and Axon Region 3 (p = 
0.8780, 0.9970). (E) TPH2 integrated density comparison between SAL, FLX, and AF groups for 
Axon Region 1 (p = 0.9518, 0.9931), Axon Region 2 (p = 0.9931, 0.7366), and Axon Region 3 (p 
= 0.8986, 0.9016). (D) TPH2 puncta comparison between SAL, FLX, and AF groups for Axon 
Region 1 (p = 0.9721, 0.9977), Axon Region 2 (p = 0.9521, 0.9765), and Axon Region 3 (p = 
0.1185, 0.1127). 
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